FRA
AMRX icon

Front Row Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Front Row Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-67
Closed -$1K – 1029
2019
Q1 		$1K Hold
67
– – ﹤0.01% 922
2018
Q4 		$1K Sell
67
-41
-38% -$739 ﹤0.01% 897
2018
Q3 		$2K Buy
+108
New +$2.27K ﹤0.01% 763

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Front Row Advisors's AMRX Position: Q2 2019 in Review

Front Row Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q2 2019, closing a stake of 67 shares — an estimated $1K sold.

Front Row Advisors first reported a position in AMRX in Q3 2018 and held it in 3 quarters. The position peaked at $2K in Q3 2018. 129 funds tracked by Wall St. Rank hold AMRX as of Q2 2019.

  • Front Row Advisors reported no remaining Amneal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Front Row Advisors sold 67 Amneal Pharmaceuticals shares in Q2 2019, an estimated $1K.
  • Front Row Advisors first reported a position in Amneal Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • Front Row Advisors's Amneal Pharmaceuticals position peaked at $2K in Q3 2018.
  • 129 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2019.

Based on Front Row Advisors's 13F filing for Q2 2019, filed 27 Aug 2019.